Dansk | English
Sitemap
youtube_off.png
linkedin_off.png
Facebook
News

News

Dato
19.05.2015
K. Peter Hirth, PhD, Joins Iconic Therapeutics as Board Member and Senior Scientific Advisor
South San Francisco, CA – May 12, 2015 – Iconic Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to translating an understanding of Tissue Factor biology to new therapeutics for retinal disease and cancer, today announced that K. Peter Hirth, PhD, co-founder and formerly Chief Executive Officer of Plexxikon, Inc., has been named a Director of the company and will work closely with Iconic’s leadership team as a Senior Scientific Advisor.  Dr. Hirth has over 30 years of biotechnology and pharmaceutical discovery and development experience and currently serves as a Board member of Spinomix, KineMed, Kolltan Pharmaceuticals, and Afferent Pharmaceuticals. 
Dato
19.05.2015
BONESUPPORT EARNS FROST & SULLIVAN’S 2015 BEST PRACTICES AWARD FOR ITS NOVEL PRODUCT, CERAMENT™
Lund, Sweden, (PRNEWSWIRE) May 13, 2015 – BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced that it has received the Frost & Sullivan 2015 Growth Capital Investment Award for outstanding achievement and superior performance in the area of technological innovation and strategic product development in the orthopedic biomaterial market with its proprietary product, CERAMENT™. CERAMENT™ is a platform technology currently available under four product lines:  CERAMENT™|G, CERAMENT™|V, CERAMENT™|BONE VOID FILLER and CERAMENT™| SPINE SUPPORT. CERAMENT™|G and CERAMENT™|V are the only approved injectable bone substitutes with antibiotics indicated to promote and protect bone healing in the management of bone infection.
Dato
19.05.2015
PSIOXUS THERAPEUTICS RAISES A £25M SERIES C INVESTMENT TO PROGRESS ONCOLYTIC VIRUS PLUS CHECKPOINT INHIBITOR COMBINATION STUDY IN METASTATIC COLORECTAL CANCER
OXFORD, UK – 19 May 2015 – PsiOxus Therapeutics Ltd. (PsiOxus), the oncolytic immuno-oncology company, has closed a Series C financing round of £25 million (c$38.5 million) to progress its lead clinical candidate, enadenotucirev, and a pipeline of follow-on oncolytic programmes from the antibody ‘armed’ series of AbEnAd viruses.
Dato
06.05.2015
ACACIA PHARMA ANNOUNCES POSITIVE RESULTS FROM PHASE 2 STUDY WITH APD403 IN CHEMOTHERAPY INDUCED NAUSEA & VOMITING (CINV)

Primary endpoint of preventing delayed CINV met with high significance

Cambridge, UK – 6th May 2015: Acacia Pharma Ltd (“Acacia Pharma” or “the Company”), a specialty pharmaceutical company developing supportive care products for post-surgical and cancer patients in the US and international markets, announces positive results from its Phase 2 study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV).

Dato
30.04.2015
BONESUPPORT ANNOUNCES CE-MARK OF CERAMENT™|V, THE FIRST INJECTABLE VANCOMYCIN ELUTING BONE SUBSTITUTE IN THE MANAGEMENT OF OSTEOMYELITIS
Lund, Sweden, (PRNEWSWIRE) April 29, 2015 – BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced that it has received CE-mark for CERAMENT™|V, the first injectable vancomycin eluting bone substitute indicated to promote and protect bone healing in the management of osteomyelitis.  CERAMENT™|V is an extension of the company’s antibiotic eluting bone substitute portfolio which includes CERAMENT™|G, the first injectable gentamicin eluting bone substitute.  Vancomycin is used to treat gram-positive bacteria that are known to be resistant to most antibiotics, including Methicillin-resistant Staphylococcus aureus (MRSA).  The Infectious Disease Society of America recommends vancomycin as first-line therapy for these complicated infections, which include bone, and joint infections. The company is launching CERAMENT™|V immediately in all CE-mark countries.
Dato
21.04.2015
scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery
Novel formulation and proprietary patch pump would offer a new and different option for the management of fluid overload in heart failure.
Dato
21.04.2015
ACACIA PHARMA INITIATES PHASE 3 COMBINATION PROPHYLAXIS STUDY WITH APD421 IN POST-OPERATIVE NAUSEA & VOMITING (PONV)
Cambridge, UK – 21st April 2015: Acacia Pharma Ltd (“Acacia Pharma” or “the Company”), the supportive care company developing  products for US and international markets, announces the initiation of a Phase 3 study investigating APD421 in combination with standard antiemetics, in the prevention of post-operative nausea & vomiting (PONV) in high-risk patients. PONV remains a clinically significant problem in patients undergoing surgery, despite the availability of a range of anti-emetic medications. International consensus guidelines recommend the use of multiple anti-emetics to prevent PONV in high-risk patients.
Dato
20.04.2015
PSIOXUS THERAPEUTICS TO PRESENT PROMISING NEW DATA ON NOVEL ONCOLYTIC IMMUNONCOLOGY PLATFORM AT AACR 2015
OXFORD, UK – 16 April 2015 – PsiOxus Therapeutics Ltd. (PsiOxus), an oncolytic immunoncology company, has announced that it will present data highlighting the progress of its next generation “Antibody Armed EnAd” (AbEnAd) anti-cancer therapeutic platform at the American Association for Cancer Research (AACR) Annual Meeting 2015 in Philadelphia, PA April 19-22, 2015. AbEnAd is the antibody armed series from the “Armed EnAd Platform” which is based upon the company’s flagship therapeutic oncolytic virus, enadenotucirev (EnAd). EnAd was developed using the principles of natural selection to specifically target and destroy cancer cells, and to allow systemic intravenous delivery.
Dato
20.04.2015
PSIOXUS THERAPEUTICS EXPANDS CLINICAL STUDIES FOR IMMUNO-ONCOLYTIC TREATMENT FOLLOWING POSITIVE RESPONSE TO INTRAVENOUS DELIVERY
Phase I Study Results Confirming Intravenous Delivery Profile and Repeated Dosing Leads to Expansion of the Clinical Programme into New Indications
Dato
16.04.2015
BONESUPPORT CLOSES $14 MILLION IN FUNDING LED BY MAJOR SCANDINAVIAN PENSION FUND
Financing will be used to grow CERAMENT™ platform and expand market penetration
Forrige Forrige 10 11 12 13 14 15 16 17 18 19 20 Næste 10 Næste